These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 2111969)

  • 1. Phase II assessment of recombinant leukocyte A interferon with difluoromethylornithine in disseminated malignant melanoma.
    Creagan ET; Long HJ; Ahmann DL; Schaid DJ
    Am J Clin Oncol; 1990 Jun; 13(3):218-20. PubMed ID: 2111969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disseminated malignant melanoma and recombinant interferon: analysis of seven consecutive phase II investigations.
    Creagan ET; Schaid DJ; Ahmann DL; Frytak S
    J Invest Dermatol; 1990 Dec; 95(6 Suppl):188S-192S. PubMed ID: 2124246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma.
    Mittelman A; Huberman M; Puccio C; Fallon B; Tessitore J; Savona S; Eyre R; Gafney E; Wick M; Skelos A
    Cancer; 1990 Aug; 66(4):664-9. PubMed ID: 2386896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of recombinant leukocyte A interferon (IFN-alpha 2A) plus 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and the combination cimetidine with BCNU in patients with disseminated malignant melanoma.
    Morton RF; Creagan ET; Schaid DJ; Kardinal CG; McCormack GW; McHale MS; Wiesenfeld M
    Am J Clin Oncol; 1991 Apr; 14(2):152-5. PubMed ID: 2028922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study.
    Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B
    Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dacarbazine (DTIC) and human recombinant interferon alpha 2a (Roferon) in the treatment of disseminated malignant melanoma.
    Mulder NH; Willemse PH; Schraffordt Koops H; de Vries EG; Sleijfer DT
    Br J Cancer; 1990 Dec; 62(6):1006-7. PubMed ID: 2257203
    [No Abstract]   [Full Text] [Related]  

  • 8. Three consecutive phase II studies of recombinant interferon alfa-2a in advanced malignant melanoma. Updated analyses.
    Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
    Cancer; 1987 Feb; 59(3 Suppl):638-46. PubMed ID: 10822463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients.
    Creagan ET; Ahmann DL; Frytak S; Long HJ; Chang MN; Itri LM
    Cancer Treat Rep; 1986 May; 70(5):619-24. PubMed ID: 3518925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
    Eton O; Buzaid AC; Bedikian AY; Smith TM; Papadopoulos NE; Ellerhorst JA; Hibberts JL; Legha SS; Benjamin RS
    Cancer; 2000 Apr; 88(7):1703-9. PubMed ID: 10738230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
    Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
    Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of difluoromethylornithine in combination with recombinant alpha 2a-interferon.
    Edmonson JH; Kovach JS; Buckner JC; Kvols LK; Hahn RG
    Cancer Res; 1988 Nov; 48(22):6584-6. PubMed ID: 3141046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of continuous subcutaneous interferon-alfa combined with cisplatin in advanced malignant melanoma.
    Richner J; Joss RA; Goldhirsch A; Brunner KW
    Eur J Cancer; 1992; 28A(6-7):1044-7. PubMed ID: 1627370
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difluoromethylornithine and leukocyte interferon: a phase I study in cancer patients.
    Talpaz M; Plager C; Quesada J; Benjamin R; Kantarjian H; Gutterman J
    Eur J Cancer Clin Oncol; 1986 Jun; 22(6):685-9. PubMed ID: 3091371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of high-dose bolus interleukin-2 and interferon alfa-2a in patients with metastatic malignancy.
    Budd GT; Murthy S; Finke J; Sergi J; Gibson V; Medendorp S; Barna B; Boyett J; Bukowski RM
    J Clin Oncol; 1992 May; 10(5):804-9. PubMed ID: 1569452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.
    García M; del Muro XG; Tres A; Crespo C; Valladares M; López JJ; Rifà J; Pérez X; Filipovich E; Germà-Lluch JR
    Melanoma Res; 2006 Aug; 16(4):365-70. PubMed ID: 16845333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of recombinant leukocyte A interferon (IFN-alpha 2A, Roferon-A) with doxorubicin in advanced malignant disease.
    Creagan ET; Frytak S; Long HJ; Kvols LK
    Cancer; 1989 Sep; 64(5):1034-7. PubMed ID: 2474365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
    Schiller JH; Hawkins MJ; O'Connell MJ; Sielaff K; Borden EC
    J Biol Response Mod; 1989 Jun; 8(3):252-61. PubMed ID: 2746297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interferon ALFA-2A in combination with carboplatin, vinblastine, and bleomycin in the treatment of advanced malignant melanoma.
    Bafaloukos D; Pavlidis N; Fountzilas G; Skarlos D; Klouvas G; Makrantonakis P; Giannakakis T; Tsavaris N; Kosmidis P
    Am J Clin Oncol; 1996 Jun; 19(3):296-300. PubMed ID: 8638545
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-alpha and chemohormonal therapy for patients with advanced melanoma: final results of a phase I-II study of the Cancer Biotherapy Research Group and the Mid-Atlantic Oncology Program.
    Stark JJ; Dillman RO; Schulof R; Wiemann MC; Barth NM; Honeycutt PJ; Soori G
    Cancer; 1998 May; 82(9):1677-81. PubMed ID: 9576288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.